Melatonin in Cancer Management: Progress and Promise.
From: Department of Dermatology, University of Wisconsin, Madison, WI 53706, USA.
Cancer research
- Publish Date: Oct 2006
- ISSN: 0008-5472
- Volume: 66
- Issue: 20
- Pages: 9789-93
- Medium: Print
- Language: English
- Citation (JAMA): Jung Brittney, Ahmad Nihal, et al. Melatonin in Cancer Management: Progress and Promise.. Cancer Res. Oct 2006;66:9789-93
Abstract
Physiologic and pharmacologic concentrations of the pineal hormone melatonin have shown chemopreventive, oncostatic, and tumor inhibitory effects in a variety of in vitro and in vivo experimental models of neoplasia. Multiple mechanisms have been suggested for the biological effects of melatonin. Not only does melatonin seem to control development alone but also has the potential to increase the efficacy and decrease the side effects of chemotherapy when used in adjuvant settings. This review critically evaluates progress in the ability of melatonin to prevent or reverse cancer development and progression. We also discuss future prospects of the possible development of melatonin as a chemopreventive agent.
Mesh Headings (Keywords): Animals, Anticarcinogenic Agents, Antineoplastic Agents, Clinical Trials as Topic, Humans, Melatonin, Neoplasms
Check for Full Text / PubMed Unique Identifier (PMID): 17047036
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.